Duolingo Inc vs Johnson & Johnson — how do they compare? Duolingo Inc trades at $133.59 (market cap $6.34B), while Johnson & Johnson trades at $261.2 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 98.8× Duolingo Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| DUOL | JNJ | |
|---|---|---|
Market Cap | $6.34B | $626.09B |
Sector | Technology | Health |
52-Week High | $369.19 | $267.24 |
52-Week Low | $90.03 | $172.78 |
Enterprise Value | $5.11B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
Duolingo trades at $131.94, down 3.83% amid mixed signals. The stock shows strong fundamentals with revenue growing from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $129. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.
The outlook remains cautiously optimistic with 30% analyst buy ratings but significant execution risk. Growth investments pressure near-term margins while user engagement strengthens. Key risks include monetization challenges and competitive threats in the edtech space. The consensus price target of $121 suggests limited upside from current levels.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →